Boehringer Ingelheim Announces Results From Two New Analyses Evaluating Idarucizumab

Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran.One analysis examined reinitiation of antithrombotic therapy after administration of idarucizumab.1 The reinitiation of antithrombotic therapy in patients with nonvalvular atrial fibrillation (AF) is important in order to address the underlying risk of stroke.

URL:
businesswire.com/news/home/20151109006951/en/Boehringer-Ingelheim-Presents-idarucizumab-Praxbind%C2%AE-Analyses-Reintroduction

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: